Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group

Lancet. 1999 Mar 27;353(9158):1040-4. doi: 10.1016/s0140-6736(98)05069-7.

Abstract

Background: For patients with critical limb ischaemia, spinal-cord stimulation has been advocated for the treatment of ischaemic pain and the prevention of amputation. We compared the efficacy of the addition of spinal-cord stimulation to best medical treatment in a randomised controlled trial.

Methods: 120 patients with critical limb ischaemia not suitable for vascular reconstruction were randomly assigned either spinal-cord stimulation in addition to best medical treatment or best medical treatment alone. Primary outcomes were mortality and amputation. The primary endpoint was limb survival at 2 years.

Findings: The mean (SD) age of the patients was 72.6 years (10.3). Median (IQR) follow-up was 605 days (244-1171). 40 (67%) of 60 patients in the spinal-cord-stimulator group and 41 (68%) of 60 patients in the standard group were alive at the end of the study, (p=0.96). There were 25 major amputations in the spinal-cord-stimulator group and 29 in the standard group, (p=0.47). The hazard ratio for survival at 2 years without major amputation in the spinal-cord stimulation group compared with the standard group was 0.96 (95% CI 0.61-1.51).

Interpretation: Spinal-cord-stimulation in addition to best medical care does not prevent amputation in patients with critical limb ischaemia.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amputation, Surgical / statistics & numerical data
  • Costs and Cost Analysis
  • Electric Stimulation Therapy* / adverse effects
  • Female
  • Humans
  • Ischemia / drug therapy
  • Ischemia / mortality
  • Ischemia / therapy*
  • Leg / blood supply*
  • Male
  • Narcotics / therapeutic use
  • Pain / drug therapy
  • Pain Measurement
  • Reference Values
  • Risk Factors
  • Spinal Cord*
  • Survival Analysis

Substances

  • Narcotics